ArticleOncogene2026
Aberrant splicing in human cancer shows possible functional impact on transcription factors.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Cancer shows aberrant alternative splicing (AS), which could functionally perturb proteins required for normal cellular behavior. Transcription factors (TFs) are proteins that regulate gene transcription. Some evidence about AS-driven perturbation of TFs in cancer has been documented. A systematic analysis of how cancer-specific AS could affect structural or functional characteristics of TFs is missing. Such an analysis could reveal the molecular mechanisms of cancer progression due to transcription misregulations, and thus could help identify therapeutic targets. Here, we systematically analyzed AS-induced structural and potential functional perturbations of TFs across 15 cancer types. We identified 2170 perturbed AS events (i.e., events showing significant AS pattern differences between normal and paired cancer samples) that affect 727 TFs across 14 cancer types. In 205 TFs, the perturbed AS events affect known functional domains of TFs. Additional evidence for a potential functional impact of cancer-specific AS on TFs was also found by (1) relating AS patterns of the perturbed AS events with the DNA-binding and regulatory activity of TFs and (2) using cancer dependency data to explore whether the affected TFs are essential for cancer cell line proliferation. Our findings show a large-scale, likely functional, perturbation of TFs due to cancer-specific AS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.